{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:56:17Z","timestamp":1792587377755,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","award":["\/2025\/346"],"award-info":[{"award-number":["\/2025\/346"]}],"id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","award":["MLP-21003"],"award-info":[{"award-number":["MLP-21003"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109232","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:24:19Z","timestamp":1763083459000},"page":"109232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of kenpaullone derivatives as potential dual inhibitors of cholinesterases and glycogen synthase kinase-3\u03b2"],"prefix":"10.1016","volume":"167","author":[{"given":"Rinky","family":"Raghuvanshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish C.","family":"Wakudkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Manda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip B.","family":"Bharate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109232_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","article-title":"Alzheimer's disease hypothesis and related therapies","volume":"7","author":"Du","year":"2018","journal-title":"Transl. Neurodegener."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109232_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"Ekavali, a review on Alzheimer\u2019s disease pathophysiology and its management: an update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109232_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/acschemneuro.8b00409","article-title":"Connecting the dots: linking the biochemical to morphological transitions in Alzheimer\u2019s disease","volume":"10","author":"Baig","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109232_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000507569","article-title":"Translational scoring of candidate treatments for Alzheimer\u2019s disease: a systematic approach","volume":"49","author":"Cummings","year":"2020","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109232_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109232_bb0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1021\/acschemneuro.8b00069","article-title":"Alzheimer\u2019s disease, the \u201cone-molecule, one-target\u201d paradigm, and the multitarget directed ligand approach","volume":"9","author":"Oset-Gasque","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"27","key":"10.1016\/j.bioorg.2025.109232_bb0035","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2174\/1568026617666170707130652","article-title":"Multi-targeting strategies for Alzheimer's disease therapeutics: pros and cons","volume":"17","author":"Das","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109232_bb0040","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109232_bb0045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1017\/S1092852919000245","article-title":"Lumateperone (ITI-007) for the treatment of schizophrenia: overview of placebo-controlled clinical trials and an open-label safety switching study","volume":"24","author":"Vanover","year":"2019","journal-title":"CNS Spectr."},{"issue":"4558","key":"10.1016\/j.bioorg.2025.109232_bb0050","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"issue":"4011","key":"10.1016\/j.bioorg.2025.109232_bb0055","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1126\/science.174.4011.788","article-title":"The cholinergic synapse and the site of memory","volume":"174","author":"Deutsch","year":"1971","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109232_bb0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exnr.2000.7397","article-title":"On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis","volume":"163","author":"Bartus","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2025.109232_bb0065","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3245935","article-title":"Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease","volume":"2016","author":"Panza","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"26","key":"10.1016\/j.bioorg.2025.109232_bb0070","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1016\/j.febslet.2006.10.033","article-title":"PKA modulates GSK-3\u03b2- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners","volume":"580","author":"Liu","year":"2006","journal-title":"FEBS Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109232_bb0075","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1523\/JNEUROSCI.0889-12.2012","article-title":"Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease","volume":"32","author":"Hurtado","year":"2012","journal-title":"J. Neurosci."},{"issue":"6938","key":"10.1016\/j.bioorg.2025.109232_bb0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nature01640","article-title":"GSK-3\u03b1 regulates production of Alzheimer's disease amyloid-\u03b2 peptides","volume":"423","author":"Phiel","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109232_bb0085","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2013.04.065","article-title":"Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease","volume":"435","author":"Noh","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109232_bb0090","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1074\/jbc.M112.409250","article-title":"Inhibition of glycogen synthase kinase-3 ameliorates \u03b2-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model","volume":"288","author":"Avrahami","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2013.10.001","article-title":"Glycogen synthase kinase-3 reduces acetylcholine level in striatum via disturbing cellular distribution of choline acetyltransferase in cholinergic interneurons in rats","volume":"255","author":"Zhao","year":"2013","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.bioorg.2025.109232_bb0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuint.2013.07.003","article-title":"Inhibition of glycogen synthase kinase-3\u03b2 by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes","volume":"63","author":"Wang","year":"2013","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109232_bb0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cellsig.2008.10.014","article-title":"Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity","volume":"21","author":"Yuskaitis","year":"2009","journal-title":"Cell. Signal."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109232_bb0110","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1021\/acs.jmedchem.1c00160","article-title":"Discovery of novel tacrine-pyrimidone hybrids as potent dual AChE\/GSK-3 inhibitors for the treatment of Alzheimer's disease","volume":"64","author":"Yao","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109232_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","article-title":"Dual GSK-3\u03b2\/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer's disease drug discovery","volume":"9","author":"Jiang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109232_bb0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejmech.2018.12.063","article-title":"Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3","volume":"168","author":"Oukoloff","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112751","article-title":"Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease","volume":"207","author":"Jiang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115940","article-title":"Discovery of potent glycogen synthase kinase 3\/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease","volume":"30","author":"Jiang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0135","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/707468","article-title":"Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease","author":"Berk","year":"2012","journal-title":"Int. J. Alzheimer's Dis."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109232_bb0140","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/17425255.4.10.1363","article-title":"Donepezil: potential neuroprotective and disease-modifying effects","volume":"4","author":"Jacobson","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109232_bb0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2006.04.007","article-title":"Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade","volume":"51","author":"Takada-Takatori","year":"2006","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109232_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejphar.2007.12.009","article-title":"Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice","volume":"581","author":"Saxena","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109232_bb0155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejmech.2018.09.031","article-title":"Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease","volume":"158","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2025.109232_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400384","article-title":"N-Benzyl piperidine Fragment in Drug Discovery","volume":"19","author":"Sharma","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.109232_bb0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ejmech.2017.02.043","article-title":"Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer\u2019s disease","volume":"130","author":"Dias","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","article-title":"Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease","volume":"75","author":"Bautista-Aguilera","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109232_bb0175","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","article-title":"Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer\u2019s disease: the design of donecopride","volume":"58","author":"Rochais","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0180","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejmech.2019.02.030","article-title":"Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer\u2019s disease","volume":"167","author":"Sharma","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109232_bb0185","article-title":"Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer\u2019s disease models","volume":"2012","author":"Kramer","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109232_bb0190","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1046\/j.1432-1327.2000.01673.x","article-title":"Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5\/p25","volume":"267","author":"Leost","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109232_bb0195","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1021\/jm701582f","article-title":"9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication","volume":"51","author":"Stukenbrock","year":"2008","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2025.109232_bb0200","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/jm9900570","article-title":"Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1\/cyclin B inhibition, and in vitro antitumor activity","volume":"42","author":"Schultz","year":"1999","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109232_bb0205","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1021\/jm901388c","article-title":"Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1\/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation","volume":"53","author":"Egert-Schmidt","year":"2010","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109232_bb0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/adt.2006.029","article-title":"A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors","volume":"5","author":"Baki","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.bioorg.2025.109232_bb0215","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109232_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153659","article-title":"Identification of plant-based multitargeted leads for Alzheimer\u2019s disease: in-vitro and in-vivo validation of Woodfordia fruticosa (L.) Kurz","volume":"91","author":"Raghuvanshi","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2025.109232_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112761","article-title":"Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase","volume":"207","author":"Abdullaha","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109232_bb0230","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.bmcl.2015.02.013","article-title":"Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery","volume":"25","author":"Bharate","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109232_bb0235","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jmb.2003.08.031","article-title":"Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors","volume":"333","author":"Bertrand","year":"2003","journal-title":"J. Mol. Biol."},{"issue":"22","key":"10.1016\/j.bioorg.2025.109232_bb0240","doi-asserted-by":"crossref","first-page":"10282","DOI":"10.1021\/jm300871x","article-title":"Structures of human acetylcholinesterase in complex with pharmacologically important ligands","volume":"55","author":"Cheung","year":"2012","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109232_bb0245","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/molecules22122098","article-title":"Comparison of the binding of reversible inhibitors to human butyrylcholinesterase and acetylcholinesterase: a crystallographic, kinetic and calorimetric study","volume":"22","author":"Rosenberry","year":"2017","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109232_bb0250","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1021\/acs.jcim.7b00095","article-title":"Identification of potent and selective CYP1A1 inhibitors via combined ligand and structure-based virtual screening and their in vitro validation in sacchrosomes and live human cells","volume":"57","author":"Joshi","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"36","key":"10.1016\/j.bioorg.2025.109232_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202403696","article-title":"Computational analysis of phase I metabolism in clinically studied flavoalkaloids: molecular docking, MMGBSA binding energy calculations, and molecular dynamics simulations","volume":"9","author":"Kallurkar","year":"2024","journal-title":"ChemistrySelect"},{"issue":"9","key":"10.1016\/j.bioorg.2025.109232_bb0260","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tips.2004.07.006","article-title":"Pharmacological inhibitors of glycogen synthase kinase 3","volume":"25","author":"Meijer","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"17","key":"10.1016\/j.bioorg.2025.109232_bb0265","doi-asserted-by":"crossref","first-page":"7700","DOI":"10.1021\/acs.jmedchem.8b00669","article-title":"Development of second-generation CDK2 inhibitors for the prevention of cisplatin-induced hearing loss","volume":"61","author":"Hazlitt","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109232_bb0270","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ddr.21544","article-title":"Identification of embelin, a 3-undecyl-1,4-benzoquinone from Embelia ribes as a multitargeted anti-Alzheimer agent","volume":"80","author":"Nuthakki","year":"2019","journal-title":"Drug Dev. Res."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2025.109232_bb0275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cbi.2010.01.042","article-title":"Acetylcholinesterase: from 3D structure to function","volume":"187","author":"Dvir","year":"2010","journal-title":"Chem. Biol. Interact."},{"issue":"20","key":"10.1016\/j.bioorg.2025.109232_bb0280","doi-asserted-by":"crossref","first-page":"11953","DOI":"10.1074\/jbc.271.20.11953","article-title":"The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors","volume":"271","author":"Ordentlich","year":"1996","journal-title":"J. Biol. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T21:37:06Z","timestamp":1766093826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825011125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"alternative-id":["S0045206825011125"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109232","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of kenpaullone derivatives as potential dual inhibitors of cholinesterases and glycogen synthase kinase-3\u03b2","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109232"}}